Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity (Q34690068)

4 August 2017

1 reference

title

Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity (English)

1 reference

4 August 2017

1 reference

0 references

1 reference

Ries F

1

1 reference

4 August 2017

Klastersky J

series ordinal

2

1 reference

4 August 2017

language of work or name

1 reference

1 November 1986

1 reference

American Journal of Kidney Diseases

4 August 2017

published in

1 reference

4 August 2017

volume

8

1 reference

4 August 2017

issue

5

1 reference

4 August 2017

page(s)

368-379

1 reference

The renal toxicity of cancer chemotherapeutic agents

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

The clinical pharmacology of methotrexate.new applications of an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

New approaches to cancer chemotherapy with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Pharmacokinetics of high-dose methotrexate treatment in children

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Methotrexate and hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Hemoperfusion for methotrexate removal

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Chronic Renal Failure in Children Treated with Methyl CCNU

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Nephrotoxicity of nitrosoureas

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Nephrotoxicity of Methyl-CCNU

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Effects of prochlorperazine on experimental nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Streptozotocin therapy for metastatic insulinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Islet cell tumors: current concepts and management

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Clinical antitumor activity and toxicity of streptozotocin (NSC-85998)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Metabolic and toxic effects of mithramycin during tumor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Control of hypercalcemia with mithramycin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Mitomycin C: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

BIOLOGICAL STUDIES OF ANTICANCER AGENTS. I. EFFECTS OF PROLONGED INTRAPERITONEAL INJECTIONS OF MITOMYCIN C ON THE URINARY ORGANS

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Induction of Hydronephrosis by Prolonged Intraperitoneal Injections of Sub-toxic Dose of Mitomycin C in Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Renal toxicity in man treated with mitomycin C

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Microangiopathic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Renal disease after mitomycin C therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Intravascular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil and mitomycin-C

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Mitomycin-induced haemolysis and renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Haemolysis and renal impairment syndrome in patients on 5-fluorouracil and mitomycin-C.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Platinum Compounds: a New Class of Potent Antitumour Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Antileukaemic and Nephrotoxic Properties of Platinum Compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

cis-Dichlorodiammineplatinum(II) (NSC-119 875): preclinical toxicologic evaluation of intravenous injection in dogs, monkeys and mice

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Preliminary clinical experience withcis-diamminedichloroplatinum (II) (NSC 119875, CACP)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Cis-diamminedichloroplatinum (II). A new anticancer drug

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

The Role of cis-Platinum in Solid-Tumor Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Platinum nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

The renal pathology in clinical trials of cis-platinum (II) diamminedichloride

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Platinum nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Nephrotoxicity of cis-platinum (II) dichlorodiammine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Kinetics of cis-dichlorodiammineplatinum

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Lack of age-dependent cisplatin nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Comparison of methods of evaluating nephrotoxicity of cis-platinum

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Urinary excretion of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase in patients receiving amikacin or cis-platinum

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Hypomagnesemia and Renal Magnesium Wasting in Patients Receiving Cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Renal and electrolyte disturbances associated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Pathogenesis of hypocalcemia in primary hypomagnesemia: normal end-organ responsiveness to parathyroid hormone, impaired parathyroid gland function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

The influence of aminoglycosides on the nephrotoxicity of cis-diamminedichloroplatinum in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

High-Dose Cisplatin in Hypertonic Saline

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

High-dose cisplatin in patients with advanced malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

24-hour infusion of cis-platinum in head and neck cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Continuous Infusion or Bolus Injection in Cancer Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Intraperitoneal cisplatin with systemic thiosulfate protection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Effects of the diuretics mannitol or acetazolamide on nephrotoxicity and physiological disposition of cisplatin in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

Phase I study of carboplatin given on a five-day intravenous schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980112-3

7 January 2021

10.1016/S0272-6386(86)80112-3

Identifiers

DOI

1 reference

4 August 2017

1 reference